RCEL vs. NPCE, UTMD, ANGO, PROF, DCTH, OBIO, DRTS, INO, SGHT, and TLSI
Should you be buying AVITA Medical stock or one of its competitors? The main competitors of AVITA Medical include NeuroPace (NPCE), Utah Medical Products (UTMD), AngioDynamics (ANGO), Profound Medical (PROF), Delcath Systems (DCTH), Orchestra BioMed (OBIO), Alpha Tau Medical (DRTS), Inovio Pharmaceuticals (INO), Sight Sciences (SGHT), and TriSalus Life Sciences (TLSI). These companies are all part of the "surgical & medical instruments" industry.
AVITA Medical (NASDAQ:RCEL) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation.
In the previous week, AVITA Medical had 16 more articles in the media than NeuroPace. MarketBeat recorded 21 mentions for AVITA Medical and 5 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.15 beat AVITA Medical's score of 0.03 indicating that NeuroPace is being referred to more favorably in the news media.
NeuroPace has a net margin of -45.61% compared to AVITA Medical's net margin of -88.41%. AVITA Medical's return on equity of -84.07% beat NeuroPace's return on equity.
AVITA Medical presently has a consensus target price of $24.60, indicating a potential upside of 194.26%. NeuroPace has a consensus target price of $15.67, indicating a potential upside of 96.08%. Given AVITA Medical's higher possible upside, research analysts plainly believe AVITA Medical is more favorable than NeuroPace.
27.7% of AVITA Medical shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 1.8% of AVITA Medical shares are held by company insiders. Comparatively, 22.2% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
AVITA Medical has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500.
NeuroPace has higher revenue and earnings than AVITA Medical. NeuroPace is trading at a lower price-to-earnings ratio than AVITA Medical, indicating that it is currently the more affordable of the two stocks.
AVITA Medical received 49 more outperform votes than NeuroPace when rated by MarketBeat users. Likewise, 68.22% of users gave AVITA Medical an outperform vote while only 55.81% of users gave NeuroPace an outperform vote.
Summary
NeuroPace beats AVITA Medical on 11 of the 18 factors compared between the two stocks.
Get AVITA Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AVITA Medical Competitors List
Related Companies and Tools
